Literature DB >> 19840667

Structural basis for oseltamivir resistance of influenza viruses.

P J Collins1, L F Haire, Y P Lin, J Liu, R J Russell, P A Walker, S R Martin, R S Daniels, V Gregory, J J Skehel, S J Gamblin, A J Hay.   

Abstract

Oseltamivir, one of the two anti-neuraminidase drugs, is currently the most widely used drug against influenza. Resistance to the drug has occurred infrequently among different viruses in response to drug treatment, including A H5N1 viruses, but most notably has emerged among recently circulating A H1N1 viruses and has spread throughout the population in the absence of drug use. Crystal structures of enzyme-drug complexes, together with enzymatic properties, of mutants of H5N1 neuraminidase have provided explanations for high level oseltamivir resistance due to the common H275Y mutation, with retention of zanamivir susceptibility, and intermediate level resistance due to the N295S mutation. Complementation of enhanced NA activity due to a D344N mutation by the H275Y mutation suggests an explanation for the recent emergence and predominance of oseltamivir-resistant influenza A H1N1 viruses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19840667     DOI: 10.1016/j.vaccine.2009.07.017

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  44 in total

1.  The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses.

Authors:  Wai Lan Wu; Siu-Ying Lau; Yixin Chen; Genyan Wang; Bobo Wing-Yee Mok; Xi Wen; Pui Wang; Wenjun Song; Tianwei Lin; Kwok-Hung Chan; Kwok-Yung Yuen; Honglin Chen
Journal:  Antiviral Res       Date:  2011-11-25       Impact factor: 5.970

2.  Emerging influenza antiviral resistance threats.

Authors:  Frederick G Hayden; Menno D de Jong
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

3.  Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase.

Authors:  Nicole M Bouvier; Saad Rahmat; Natalie Pica
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study.

Authors:  Zhiwei Yang; Gang Yang; Lijun Zhou
Journal:  J Comput Aided Mol Des       Date:  2013-11-12       Impact factor: 3.686

5.  The global spread of drug-resistant influenza.

Authors:  Dennis L Chao; Jesse D Bloom; Beth F Kochin; Rustom Antia; Ira M Longini
Journal:  J R Soc Interface       Date:  2011-08-24       Impact factor: 4.118

6.  Surveillance for antiviral resistance.

Authors:  Maria C Zambon
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

7.  Modeling gene sequences over time in 2009 H1N1 influenza A virus populations.

Authors:  Natalia Goñi; Alvaro Fajardo; Gonzalo Moratorio; Rodney Colina; Juan Cristina
Journal:  Virol J       Date:  2009-12-04       Impact factor: 4.099

8.  A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance.

Authors:  Lan Huang; Yang Cao; Jianfang Zhou; Kun Qin; Wenfei Zhu; Yun Zhu; Lei Yang; Dayan Wang; Hong Wei; Yuelong Shu
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

9.  The Path of Least Resistance: Mechanisms to Reduce Influenza's Sensitivity to Oseltamivir.

Authors:  Angela M Phillips; Matthew D Shoulders
Journal:  J Mol Biol       Date:  2015-12-31       Impact factor: 5.469

10.  Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.

Authors:  Yan Wu; Feng Gao; Jianxun Qi; Yuhai Bi; Lifeng Fu; Sankar Mohan; Yuhang Chen; Xuebing Li; B Mario Pinto; Christopher J Vavricka; Po Tien; George F Gao
Journal:  J Virol       Date:  2016-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.